Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Gemcitabine in NSCLC Following Platinum Failure
NCT00182806Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2004
- Primary completion
- Sep 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Roswell Park Comprehensive Cancer Center. Started Sep 2004; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00182806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00182806.